Sagawa, N., Watanabe, Y., Mizuno, Y., et al. (2020) A Case of Toxic Epidermal Necrolysis Associated with Apalutamide Administration. Journal of Cutaneous Immunology and Allergy, 3, 134-135.
https://doi.org/10.1002/cia2.12138

has been cited by the following article:

• TITLE: Enzalutamide Associated with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) Overlap: A Case Report

  AUTHORS: Sharjeel Israr, Christopher R. Mellon, Hayley J. Springs, Asia N. Quan, Marc R. Matthews

  KEYWORDS: Prostate Cancer, Enzalutamide, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, SJS/TEN

  JOURNAL NAME: Surgical Science, Vol.12 No.12, December 31, 2021

  ABSTRACT: Enzalutamide is a hormonal therapy that blocks the action of androgens, such as testosterone in the treatment of metastatic castration-resistant prostate cancer. Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) overlap and are part of an adverse drug reaction continuum of disease, in which there is a 10% - 30% involvement of the skin surface with mucositis, blisters, skin slough, and a macular rash. A 66-year-old male was treated with enzalutamide for metastatic prostate cancer and developed SJS/TEN overlap with 25% total body surface area skin involvement. The patient received a seven-day course of cyclosporine to which he responded by re-epithelialization but succumbed to multi-organ failure. While SJS/TEN has been reported with apalutamide, to our knowledge, this is the first case of SJS/TEN overlap with enzalutamide.